Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

Author:

Corren Jonathan1,Pham Tuyet‐Hang2,Garcia Gil Esther3,Sałapa Kinga4,Ren Pin5,Parnes Jane R.6,Colice Gene7,Griffiths Janet M.2

Affiliation:

1. David Geffen School of Medicine University of CaliforniaLos Angeles (UCLA) Los Angeles California USA

2. Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology BioPharmaceuticals R&DAstraZeneca Gaithersburg Maryland USA

3. Global Medical Respiratory BioPharmaceuticals R&DAstraZeneca Barcelona Spain

4. Biometrics, Late‐stage Development, Respiratory and Immunology BioPharmaceuticals R&DAstraZeneca Warsaw Poland

5. Early Biostats and Statistical Innovation Early‐stage Development, Respiratory and Immunology BioPharmaceuticals R&DAstraZeneca Gaithersburg Maryland USA

6. Translational MedicineAmgen Thousand Oaks California USA

7. Late‐stage Development, Respiratory and Immunology BioPharmaceuticals R&DAstraZeneca Gaithersburg Maryland USA

Funder

AstraZeneca

Amgen

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference46 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung KF;Eur Respir J,2014

2. Global Initiative for Asthma.Global initiative for asthma management and prevention 2020 guidelines.https://ginasthma.org/wp‐content/uploads/2020/06/GINA‐2020‐report_20_06_04‐1‐wms.pdf. Assessed February 26 2021.

3. The prevalence of severe refractory asthma;Hekking PW;J Allergy Clin Immunol,2015

4. Characterisation of patients with severe asthma in the UK severe asthma registry in the biologic era;Jackson DJ;Thorax,2021

5. Liberty asthma QUEST: phase 3 randomized, double‐blind, placebo‐controlled, parallel‐group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate‐to‐severe asthma;Busse WW;Adv Ther,2018

Cited by 67 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Screening, identification and targeted intervention of necroptotic biomarkers of asthma;Biochemical and Biophysical Research Communications;2024-11

2. Biologics in Asthma;Immunology and Allergy Clinics of North America;2024-09

3. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19

4. Eosinophils and T2 inflammation in severe asthma;Exploration of Asthma & Allergy;2024-08-13

5. The role of IL-2 cytokine family in asthma;Cytokine;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3